APP and Alzheimer disease: Several recent evidence indicates that counteracting early APP-C-terminal fragments (CTFs) accumulation might represent relevant therapeutic interventions in AD [36], as alterations in their quantitative and qualitative productions might directly contribute to the neuronal toxicity observed in the early phases of the disease [37].